NCT00689247已完成1 期
A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) After Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Pharmacokinetic variables
研究概览
简要总结
The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers
- •A body mass index (BMI=weight/height2) of 19 to 30 kg/m2
排除标准
- •Potassium outside normal reference values
- •ECG findings outside normal range
研究组 & 干预措施
A
Experimental
AZD1305 given as oral solution
干预措施: AZD1305 (Drug)
B
Experimental
AZD1305 given as iv infusion
干预措施: AZD1305 (Drug)
结局指标
主要结局
Pharmacokinetic variables
时间窗: During all dosing visits
次要结局
- Adverse events, vital signs, ECG, laboratory variables and physical examination(During the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530HealthyNCT00771979AstraZeneca18
已完成
1 期
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)Acute Myeloid LeukaemiaNCT01019161AstraZeneca5
已完成
1 期
Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male SubjectsHealthyNCT00984477AstraZeneca100
已完成
1 期
Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male VolunteersHealthyNCT00853983AstraZeneca6
已完成
1 期
To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese SubjectsHealthyNCT00738322AstraZeneca36